Last Updated : November 22, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Semglee | insulin glargine | Diabetes mellitus, Type 1 & 2 | Withdrawn | |||
Sensipar | Cinacalcet hydrochloride | Secondary hyper-parathyroidism in chronic kidney disease | Do not list | Complete | ||
Signifor | Pasireotide diaspartate | Cushing’s disease | Do not list | Complete | ||
Signifor LAR | pasireotide | Acromegaly, adults | Active | |||
Siliq | brodalumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Silkis | Calcitriol | Psoriasis, mild to moderate plaque | Do not list | Complete | ||
Simbrinza | Brinzolamide / brimonidine | Glaucoma and ocular hypertension | List | Complete | ||
Simponi | Golimumab | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
Simponi | Golimumab | Arthritis, psoriatic | List in a similar manner | Complete | ||
Simponi | Golimumab | Ankylosing spondylitis | List in a similar manner | Complete | ||
Simponi | Golimumab | Ulcerative colitis | Do not list at the submitted price | Complete | ||
Simponi I.V. | Golimumab | Arthritis, rheumatoid | List with criteria/condition | Complete | ||
Sivextro | Tedizolid phosphate | Acute bacterial skin and skin structure infections | Withdrawn | |||
Skyrizi | risankizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Skyrizi | risankizumab | Crohn's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Slynd | drospirenone | Contraceptive, oral | Reimburse with clinical criteria and/or conditions | Complete | ||
Sogroya | somapacitan | Growth Hormone Deficiency (GHD) | Reimburse with clinical criteria and/or conditions | Complete | ||
Sohonos | palovarotene | Fibrodysplasia Ossificans Progressiva | Reimburse with clinical criteria and/or conditions | Complete | ||
Soliqua | lixisenatide + insulin glargine | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Soliris | eculizumab | Neuromyelitis optica spectrum disorder | Reimburse with clinical criteria and/or conditions | Complete | ||
Soliris | Eculizumab | Hemolytic Uremic Syndrome, Atypical | Do not list | Complete | ||
Soliris | Eculizumab | Paroxysmal nocturnal hemoglobinuria (PNH) | Do not list | Complete | ||
Soliris | Eculizumab | Atypical hemolytic uremic syndrome | N/A | Complete | ||
Soliris | eculizumab | Myasthenia Gravis (gMG), adults | Reimburse with clinical criteria and/or conditions | Complete | ||
Somatuline Autogel | Lanreotide acetate | Acromegaly | List in a similar manner to other drugs in class | Complete |